Medigene's bluebird Deal Validates TCR Technology And Immune-Oncology Strategy
Executive Summary
Medigene's collaboration with bluebird bio is a validation of its technology platform and its new immune-oncology focused strategy.
You may also be interested in...
Bluebird Casts Wide Partnering Net To Keep Advancing Cell Therapy
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.
Under The Radar: Potential Small Cap Takeover Targets
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina
Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.